Trials / Withdrawn
WithdrawnNCT01645826
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of South Florida · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if cardizem is effective in the treatment of nitric oxide non-responder pulmonary arterial hypertension.
Conditions
- Idiopathic Pulmonary Arterial Hypertension
- Primary Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Diltiazem Hydrochloride | The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks. |
| DRUG | Sugar Pill | The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration). |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2012-07-20
- Last updated
- 2018-11-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01645826. Inclusion in this directory is not an endorsement.